Evidence map›Paper›PMID 37555669›Full record

ArticleGlycobiology2023

Polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) isozyme surface charge governs charge substrate preferences to modulate mucin type O-glycosylation.

Collin J Ballard, Miya R Paserba, Earnest James Paul Daniel, Ramón Hurtado-Guerrero, Thomas A Gerken

Open access · greenAbstract read
In one paragraph

Article in Glycobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Collin J BallardDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Miya R PaserbaDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Earnest James Paul DanielDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Ramón Hurtado-GuerreroDepartment of Biomedical Engineering, The Institute for Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza 50018, Spain.
Thomas A GerkenDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Case Western Reserve University · USUniversidad de Zaragoza · ES

Funding

TR&D3. Approaches to Proteoglycan Function at Biochemical and Cellular LevelsP41GM103390 · NIGMS · UNIVERSITY OF GEORGIA · PI LIVE, DAVID H · 2012 to 2019
$14.5M
Recombinant Production of Glycosylation Enzymes for Biochem/Structural StudiesP01GM107012 · NIGMS · UNIVERSITY OF GEORGIA · PI MOREMEN, KELLEY · 2013 to 2017
$7.5M
MUCIN SITE SPECIFIC O-GLYCOSYLATIONR01CA078834 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERKEN, THOMAS A · 1999 to 2012
$3.4M
Initiation and Regulation of Mucin-Type O-GlycosylationR01GM113534 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI GERKEN, THOMAS A · 2018 to 2023
$1.6M
NCI NIH HHS R01 CA078834NIGMS NIH HHS P01 GM107012NIGMS NIH HHS P41 GM103390NIGMS NIH HHS R01 GM113534NIH HHS R01-GM113534
6 · The paper itself

Abstract

A large family of polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) initiate mucin type O-glycosylation transferring α-GalNAc from a UDP-GalNAc donor to the hydroxyl groups of Ser and Thr residues of peptides and proteins, thereby defining sites of O-glycosylation. Mutations and differential expression of several GalNAc-Ts are associated with many disease states including cancers. The mechanisms by which these isozymes choose their targets and their roles in disease are not fully understood. We previously showed that the GalNAc-Ts possess common and unique specificities for acceptor type, peptide sequence and prior neighboring, and/or remote substrate GalNAc glycosylation. In the present study, the role of flanking charged residues was investigated using a library of charged peptide substrates containing the central -YAVTPGP- acceptor sequence. Eleven human and one bird GalNAc-T were initially characterized revealing a range of preferences for net positive, net negative, or unique combinations of flanking N- and/or C-terminal charge, correlating to each isozyme's different electrostatic surface potential. It was further found that isoforms with high sequence identity (>70%) within a subfamily can possess vastly different charge specificities. Enzyme kinetics, activities obtained at elevated ionic strength, and molecular dynamics simulations confirm that the GalNAc-Ts differently recognize substrate charge outside the common +/-3 residue binding site. These electrostatic interactions impact how charged peptide substrates bind/orient on the transferase surface, thus modulating their activities. In summary, we show the GalNAc-Ts utilize more extended surfaces than initially thought for binding substrates based on electrostatic, and likely other hydrophobic/hydrophilic interactions, furthering our understanding of how these transferases select their target.

Indexed as

MucinsN-AcetylgalactosaminyltransferasesGlycosylationHumansIsoenzymesPeptidesPolypeptide N-acetylgalactosaminyltransferaseSubstrate SpecificityIsoenzymesMucinsN-AcetylgalactosaminyltransferasesPeptidesPolypeptide N-acetylgalactosaminyltransferaseelectrostatic interactionsGALNTglycosyltransferasemolecular dynamicsmucin type O-glycosylation

Identifiers

PMID37555669
PMCPMC10629720
OpenAlexW4385684831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.